

# Epidemiological Bulletin

PAN AMERICAN HEALTH ORGANIZATION

Vol. 3, No. 3, 1982

## Chagas' Disease

### Introduction

Chagas' disease, or American trypanosomiasis, is a parasitic disease caused by the hemoflagellate *Trypanosoma (Schizotrypanum) cruzi*, which is transmitted to man and other mammals mainly by hematophagous insects of the sub-family *Triatominae*. The disease occurs exclusively in the Americas, and is distributed in rural areas from Mexico to the northern part of Argentina, wherever the ecological conditions permit the vectors to come in contact with human dwellings (Fig. 1).

### The Parasite and its Biological Cycle

*T. cruzi* evolves in invertebrate hosts (triatomine bugs commonly called "kissing bugs," "barbeiros," "chinches," "chipos") and in vertebrate hosts (man, dogs, cats, rodents, and other domestic and wild mammals). The triatomine bugs become infected by ingesting blood with circulating trypanosomes from infected mammals. These blood forms evolve to metacyclic trypanosomes in eight to 10 days while in the digestive tract of the insects. These infective forms are then eliminated in the feces.

The biological cycle in the vertebrate host starts with the penetration of the infective form through the skin or the ocular conjunctiva and other mucous membranes. The parasite rapidly invades fibroblasts and adipose cells underneath the skin as well as several organs and tissues: spleen, liver, bone marrow, kidneys, nervous tissue, lymph nodes, and striated muscle (heart).

### Modes of Infection

In man, *T. cruzi* is transmitted by "contamination" with the triatomine bug feces. The transmission of the parasite can be through blood transfusion, the placenta (congenital) or through accidental contact with the blood of infected animals.

The penetration of the parasite through the ocular conjunctiva usually provokes a local inflammatory reaction characterized by painful unilateral edema of both eyelids, enlargement of the lacrimal sac without mucous secretion, and enlargement of the pre-auricular lymph nodes. This sign, called "ocular sign" or "Romaña's sign," is characteristic of the acute stage of the disease. The penetration of the parasite in other parts of the body causes a local in-

### IN THIS ISSUE ...

- Chagas' Disease
- Diseases Subject to the International Health Regulations
- Operational Aspects of Leprosy Control Programs
- Dengue in Puerto Rico
- Diarrheal Diseases
- Information on Malaria Risk for International Travellers
- Calendar of Courses and Meetings

Figure 1. Geographic distribution of Chagas' disease.



flammatory reaction called "Chagoma of inoculation." Both inflammatory reactions are due to the multiplication of the parasite in the underlying cells.

Blood transfusion is apparently the second most important way of transmission, since 1 to 15 per cent of serologic reactors have been detected among groups of blood donors examined in several Latin American countries (1).

### Vectors and Epidemiology

More than 50 species of triatomine bugs have been reported to be naturally infected with *T. cruzi*, and about a dozen are epidemiologically important as vectors. *Triatoma infestans*, *Rhodnius prolixus*, and *Triatoma dimidiata* are well adapted to the human dwelling and represent the principal vectors (2).

The public health impact of Chagas' disease is not clearly defined in most countries. Reliability of statistical data is questionable since notification of the disease is not compulsory. Despite the phenomenon of migration of the rural population into urban areas and the consequent "urbanization" of the disease in some countries, it remains basically a rural problem associated with poor socioeconomic conditions in the population, and the domestic nature of the vector.

It is estimated that at least 20 million persons in rural and urban areas are infected with *T. cruzi*. Argentina,

Brazil, Chile, Uruguay, and Venezuela are the countries where the disease has been more widely studied, and national or provincial programs to control the disease are underway.

Three types of transmission cycles of *T. cruzi* are considered: the *domestic cycle*, which is maintained by man, domestic animals (dogs, cats) and domestic triatomine bugs; the *wild cycle*, which involves rodents, marsupialia, and other wild mammals and the wild triatomine bugs, and the *peridomestic cycle*, which can be considered as a link between the other two cycles. The last cycle is integrated by the mammals (domestic rodents, marsupialia, guinea pigs, dogs, and cats) that move back and forth from the field into the human habitation, and by the wild triatomine bugs that invade the houses attracted by light or blood sources (3).

The domestic cycle is undoubtedly the most important cycle in maintaining the Chagas' infection in rural and semirural areas in Latin America, since man and animal reservoirs live together in the house. Primitive houses still existing in such areas, with walls made of adobe or bahareque and covered with thatched roofs, constitute an excellent habitat for the vectors. They live and multiply in cracks in the walls, in beds, roofs, behind pictures, and in boxes where people keep and transport clothes and other personal effects from house to house when they move (2).

Chagas recognized the role of rural housing and the environment in the epidemiology of the disease. Products used in the construction of dwellings and wood piled for cooking have been found to have a possible role in linking the parasite to man. One such example is the common use of palm tree leaves as material to build roofs and walls of houses and outbuildings. Certain vectors, such as *R. prolixus*, glue their eggs to the leaves, allowing for colonization to develop in the building. On the other hand, *T. dimidiata* has been known to inhabit wood used for cooking, and *T. infestans* can be found in cactus and wood in corrals.

The importance of the peridomestic and wild cycles is still under careful investigation. *T. cruzi* isolates of known human origin, and *T. cruzi*-like trypanosomes isolated from animals and triatomine bugs need to be studied and typed in order to better define the epidemiology of Chagas' disease. The existence of trypanosomes in domestic and wild animals which are morphologically similar to *T. cruzi* is well known, but their human infectivity and pathogenicity has not been clarified satisfactorily. Several research laboratories are currently studying the structural, biochemical, and immunopathologic characteristics of freshly isolated trypanosomes of different origins (4).

### Clinical Manifestations

The clinical manifestations of *T. cruzi* infection in man are affected primarily by intraspecific variations of the parasite, and the immune response of the host (5). The

amount of the inoculum, the number of infections, and the age and nutritional state of the host are under investigation.

The prepatent period is about five days, and the incubation period lasts from five to 10 days. The infection usually evolves into acute and chronic stages of the disease.

The *acute stage* occurs more often in the first years of life, and lasts for one to three months. Continuous moderate fever (37.5-38.5°C) and the ophthalmoglandular syndrome (Romaña's sign) are the principal symptoms reported in children and young adults. Sometimes local edema of the face is seen, especially when Romaña's sign is present, or generalized edema in infants. Splenomegaly and hepatomegaly are reported, as well as enlargement of the lymph nodes particularly in the pre-auricular and submaxillary regions. Leucocytosis is moderate, with increase of the monocytes and lymphocytes. Severe infections in children may be accompanied by tachycardia, decreased blood pressure, gallop rhythm, and electrocardiographic changes. Severe myocarditis or acute meningoencephalitis are the terminal stages in fatal cases.

The *chronic stage* of Chagas' disease manifests itself 10 to 15 years after the infection through slowly evolving heart damage, which includes cardiac enlargement. There is an asymptomatic or latent period between the acute and chronic stages, which is usually evidenced only by transient parasitemias and serologic reactivity of the patients affected.

Digestive manifestations of *T. cruzi* infections, mainly megacolon and megaesophagus, have been reported principally in central Brazil. The prevalence and severity of chagasic cardiomyopathy and digestive changes vary with the geographic region. The factors involved in this variation are under investigation (4).

In the acute stage of the disease, the interstitial edema and the inflammatory reactions produced by the multiplication of the parasite damage the contractibility of the heart muscle. In the chronic stage, these lesions are replaced by fibrosis and the damage becomes irreversible. Aneurysmal dilation of the ventricular wall or the apex may occur. Sudden death can happen due to paroxysmal tachycardia and ventricular fibrillation.

### Immunopathogenesis

The lack of relationship among parasitic nests and heart tissue lesions found in individuals with chronic chagasic cardiomyopathy had suggested that an allergic reaction could be involved in the pathogenesis of the chagasic myocarditis (Reviewed in 6, 7). One possibility would be that cell mediated immunity is involved in the origin of lesions. In fact, lymphocytes from rabbits experimentally infected with *T. cruzi* or inoculated with fractions of dead

parasites were able in vitro to destroy allogenic infected or non-infected rabbit heart cells. Moreover, the inoculation of the parasite fractions in this host induced heart lesions that histologically may resemble what could be found in infected humans. Similarly, lymphocytes from infected humans were able to react in vitro with non-infected mouse heart cells but not liver cells, and with infected and non-infected fetal human heart cells. Therefore, it seems reasonable to think that there are common antigens among *T. cruzi* and heart tissue, and that lymphocytes that would react against heart tissue are present in chagasic individuals (Rev. in 7). However, it is not yet known whether this sensitization is the origin of the lesion or a consequence of it.

In recent years, immunoglobulins (Igs) which react with the hosts' tissue have been found in patients with different clinical forms of Chagas' disease. These antibodies react against endocardium, vascular structures, and interstitium of striated muscle (Rev. in 7, 8).

These antibodies have the following characteristics (Rev. in 7-9):

- They are more commonly found in sera from cases of Chagas' disease than any other parasitic diseases or pathological conditions.
- In adults with Chagas' disease, they are more prevalent in cases with cardiac symptomatology than in asymptomatic ones.
- Their discovery, in some cases, was associated with the presence of skeletal muscle lesions, and intracellular myocardial alterations. In addition, biopsies of the cardiac and skeletal muscle of infected humans showed the existence of Ig deposits in the plasma membrane of these tissue cells.
- They have induced morphological and functional alterations in rat myocardial cells in vitro, apparently through modifications of the  $\beta$  adrenergic receptors.
- They may have in vitro influence on the postsynaptic sites of the plasma membrane of pacemaker cells, possibly acting as a partial  $\beta$  agonist.

Antibodies reacting against neurons and Schwann cells of peripheral nerves have also been found in the serum of acute and chronic cases (Rev. in 10). Since it has been suggested that the lesion of the autonomic nervous system in the cardiac muscle and digestive tract may be the pathological mechanism for the lesions, these antibodies may play an important role in the pathogeny of Chagas' disease (Rev. in 10, 11).

Absorption experiments have suggested that these antibodies cross-react with antigens shared by the parasite and the human host (Rev. in 7, 8). Recently it has been shown that the host antibody is in the laminin, a glycoprotein from the basement membrane, and that a laminin-like molecule is present in the parasite (12). On the other hand, the use of monoclonal antibodies against the dorsal

root ganglia membrane has also defined antigenic determinants which are common to *T. cruzi*, neurons, and cardiac muscle cells (13).

These findings suggested that host tissue-reacting Igs may be the origin of the cardiac lesion found in chronic Chagas' disease, which would support the earlier assumptions that pathogenesis of the disease was linked to an immunologic reaction of the host (6-8). Moreover, detection of these tissue-reacting antibodies may be a useful prognostic tool for the infection. However, later reports based on samples obtained from cases from other geographic areas confirmed the presence of tissue-reacting immunoglobulins but not their relationship between their presence and the existence of symptoms or their severity (10, 14, 15). Identification of common antigens against the parasite and its human host may nevertheless provide useful information on the host-parasite interaction. In the event that vaccination attempts are made, the production of antigenic preparations that will not cross-react with human tissue components may be carried out.

### Diagnosis

The diagnosis of Chagas' disease is based on the presence of *T. cruzi* in the blood. Xenodiagnosis, blood culture in agar, blood concentration by centrifugation, and direct fresh blood examination between slip and coverslip are the parasitologic techniques used to detect *T. cruzi* in both acute and chronic human infections.

There are also four serologic techniques which coincide in sensitivity and specificity: (a) the complement fixation test (CFT) or Guerreiro-Machado's reaction; (b) the indirect hemagglutination test (IHA); (c) the immunofluorescent test (IFA); and (d) the direct agglutination test (DA). The IHA, IFA, and DA become reactive earlier than the CFT, usually within three months after the infection; the CFT requires at least three months to become reactive. A new technique, the enzyme-linked immunosorbent assay (ELISA) is under intensive study with promising results.

A presumptive diagnosis can be established by taking into account the clinical manifestations (especially those related to chronic heart damage), reactive serologic tests (preferably two of them), and a history of having lived in an endemic area. In patients under 20 years or over 50 years of age, rheumatic heart disease and coronary atherosclerosis have to be ruled out, respectively. In endemic areas, Chagas' heart disease has to be differentiated from other myocardiopathies, and efforts to establish a parasitologic diagnosis is highly recommended.

### Treatment

Many chemical compounds have been subject to extensive studies in Chagas' disease, but at the moment only two have shown some activity against the *T. cruzi*. They are: Nifurtimox, which has a 5-nitrofur furylidene deri-

vative (Lampit, Bayer 2502)\* and Benznidazole (RO 7-1051, Radanil, Rodragen) which is a 2-nitroimidazole derivative. The drug Nifurtimox has shown experimentally in laboratory animals and in clinical trials that it is effective in the acute stage of the disease. A cure rate between 75 to 90 per cent of patients treated has been reported by several South American investigators. In the chronic stage of the disease, definite results are still under evaluation since the parasitemia disappears but the serologic reactivity remains for years after treatment. It has been observed, however, that the heart damage remains apparently stationary in patients under treatment with evolutive heart disease. The problem with this drug is its toxicity, which causes collateral symptoms such as anorexia, weight loss, nausea, vomiting, convulsions, headache, vertigo, and insomnia, which appear 15 to 20 days after the initiation of treatment, especially in adults. Children tolerate the drug very well. The dose of Nifurtimox actually recommended is between 8.5 to 12.5 mg per kg of weight, per day, during 90 to 120 days.

Benznidazole is also under careful investigation in the treatment of acute and chronic infections of the disease.

### Control

Since *T. cruzi* infection depends on the distribution of domestic *Triatominae*, control measures are, fundamentally, directed to eliminate these insects from the human environment. Insecticides and housing improvement have been the most common and successfully used control measures. Health education of the population in endemic areas is also an important aspect of control.

The most commonly used insecticides with residual action are: benzene hexachloride (BHC, HCH, gammexane), dieldrin, and a methylcarbamate (OMS-33, Baygon, propoxur). Problems have arisen concerning the high cost of these insecticides as well as the resistance shown by some of the vectors in certain areas.

The construction or repair of human dwellings seems to be a very promising and permanent control measure to eliminate or importantly reduce the *T. cruzi* transmission to man. In 1943, Dias began the first construction project in Brazil, which pioneered the concept of house improvement as a preventive measure in the control of Chagas' disease.

Since 1960 Venezuela has progressively reduced the infestation of houses by *R. prolixus* through periodical insecticide spraying and the substitution of palm roofs with tin ones in rural houses in endemic areas. The effect of such combined control measures on the transmission of *T. cruzi* has been shown by reduced seropositivity in adult and children population samples surveyed in the state of Lara

---

\*Use of trade names and commercial sources is for identification only.

in 1980-1981 (13.1 per cent), in comparison with surveys performed in 1959-1968 (44.4 per cent) when the control was established. In children 0-9 years old, the seropositivity dropped to 1.3 from 20.5 per cent in the same period (16).

In 1979, with assistance from PAHO and the Edna McConnell Clark Foundation, the Government of Venezuela began a pilot project aimed at defining the role of rural housing in the continued transmission of *T. cruzi*. The study area selected was in the State of Trujillo where the Government was in the process of modifying rural housing.

The initial construction phases of the project did not include community participation or other socioeconomic considerations. Houses were either improved or new ones built depending on the cost of repair. No modification took place unless the criteria of land ownership or property agreements were met. Improvements consisted of plastering mud walls, cementing floors, and adding zinc roofs. The new houses used a standard design with cement block walls, zinc roofs, and cement floors.

Evaluations included preconstruction and routine postconstruction, entomologic searches for vectors, xenodiagnostic examination of dogs, cats, and some domestic rodents, and serologic and electrocardiologic examination of the occupants. Similar evaluations were made in a check area in Portuguesa State receiving periodical insecticide treatment.

The housing improvement was found to significantly reduce infestation indices (from 62.4 per cent at preconstruction to 18.8, 5.2, and 2.8 per cent at, respectively, 8, 18, and 24 months postconstruction). Initially some of the modified and new houses were infested with *R. prolixus*. This was due to returning infested personal belongings to the houses. Although the study is not complete, it does demonstrate that house improvement can make houses virtually vector free for a period of time.

#### References

(1) Cerisola, J. A., et al. Enfermedad de Chagas y la transfusión de sangre. *Bol Of Sanit Panam* 73(3):203-221, 1973.

(2) Zeledón, R. and J. E. Rabinovich. Chagas' disease: An ecological appraisal with special emphasis on its insects vectors. *Ann Rev Entomol* 26:101-133, 1981.

(3) Carcavallo, R. U. Aspects of the epidemiology of Chagas' disease in Venezuela and Argentina. In *New Approaches in American Trypanosomiasis Research*. PAHO Scientific Publication 318, 1976, pp. 347-58.

(4) Miles, M. A., et al. Do radically dissimilar *Trypanosoma cruzi* strains (Zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease? *Lancet*, June 20:1338-1340, 1981.

(5) Brener, Z. and Z. Z. Andrade. O parasito: Relações hospedeiro-parásito. In *Trypanosoma cruzi e Doença de Chagas* Rio de Janeiro, Editora Guanabara Koogan, 1979, pp. 1-41.

(6) Goble, F. C. South American Trypanosomes. In G. J. Jackson, et al. (eds.), *Immunity to Parasitic Animals*, Vol. 2. New York, Appleton-Century-Crofts, 1970, pp. 597-689.

(7) Brener, Z. Immunity to *Trypanosoma cruzi*. *Adv Parasitol* 18:247-292, 1980.

(8) Schmuñis, G. A., et al. Tissue-reacting antibodies (EVI antibodies) in Nifurtimox-treated patients with Chagas' disease. *J Infect Dis* 138:401-404, 1978.

(9) Gimeno, A. L., et al. Altered inotropic and chronotropic effects of norepinephrine on isolated rat atria exposed to chagasic sera. Influences of cocaine, normetanephrine and U-0521 (3', 4'-dihydroxy-2methyl propiophenone). *Cardiovasc Res* 13:723, 1979.

(10) Szarfman, A., et al. Tissue-reacting immunoglobulins in patients with different clinical forms of Chagas' disease. *Am J Trop Med Hyg* 30:43-46, 1981.

(11) Ribeiro dos Santos, R. et al. Antibodies against neurons in chronic Chagas' disease. *Tropenmed Parasitol* 30:19-23, 1979.

(12) Szarfman, A. et al. Antibodies to Laminin in Chagas' Disease. *J Exp Med* 155:1161-1171, 1982.

(13) Wood, J. N., et al. A monoclonal antibody defining antigenic determinants on subpopulations of mammalian neurones and *Trypanosoma cruzi* parasites. *Nature* 296:34-38, 1982.

(14) Peralta, J. M., et al. Autoantibodies and chronic Chagas' heart disease. *Trans R Soc Trop Med Hyg* 75:569, 1981.

(15) Manigot, D. A., et al. Anticorpos EVI e NP na infecção chagásica crônica. Estudo em pacientes com diferentes formas clínicas. *Rev Inst Med Trop São Paulo* 24:6-10, 1982.

(16) Villalobos, L. L., et al. Enfermedad de Chagas: Situación actual en el Estado Lara. VI Congreso Venezolano de Salud Pública "Salud para todos," (mimeographed document). Dirección de Malariología y Saneamiento Ambiental, Ministerio de Sanidad y Asistencia Social, Venezuela, 1981, p. 10.

(Source: Parasitic Diseases and Vector Control, Division of Disease Prevention and Control, and Research Promotion and Coordination, Division of Human Resources and Research, PAHO.)